1. Home
  2. GSL vs HROW Comparison

GSL vs HROW Comparison

Compare GSL & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSL

Global Ship Lease Inc New

HOLD

Current Price

$44.48

Market Cap

1.5B

ML Signal

HOLD

HROW

Harrow Inc.

N/A

Current Price

$36.97

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GSL
HROW
Founded
2007
1998
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2008
2008

Fundamental Metrics

Financial Performance
Metric
GSL
HROW
Price
$44.48
$36.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$44.00
$69.86
AVG Volume (30 Days)
363.5K
532.4K
Earning Date
05-18-2026
05-11-2026
Dividend Yield
6.34%
N/A
EPS Growth
N/A
71.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$31.62
Revenue Next Year
N/A
$50.77
P/E Ratio
$3.49
N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.28
$28.54
52 Week High
$45.45
$54.98

Technical Indicators

Market Signals
Indicator
GSL
HROW
Relative Strength Index (RSI) 59.19 39.88
Support Level $37.00 $32.74
Resistance Level $45.07 $42.40
Average True Range (ATR) 0.98 1.85
MACD 0.05 -0.34
Stochastic Oscillator 75.63 14.71

Price Performance

Historical Comparison
GSL
HROW

About GSL Global Ship Lease Inc New

Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: